AMENDMENT UNDER 37 C.F.R. § 1.111 U.S. Patent Application No.: 10/535,414

### **AMENDMENTS TO THE SPECIFICATION**

Please replace Table 1a of the specification, previously amended July 6, 2009, with the following amended table:

Table 1a

List of probes informative for disease diagnosis

	Clone ID	No. of nucleotides	SEQ ID NO: in sequence listing
1	I-24	373	11
2	I-28	564	13
3	I-30	622	398
4	I-34	554	15
5	I-54	<del>156</del> <u>155</u>	399
6	I-58	554	24
7	II-03	622	34
8	II-05	628	35
9	II-06	<del>528</del> <u>527</u>	36
10	II-10	329	39
11	II-24	534	47
12	II-25	444	48
13	II-26	566	49
14	II-33	523	55
15	II-34	566	56
16	II-41	534	60
17	II-42	512	61
18	II-57	505	73
19	II-61	596	77
20	II-69	387	85
21	II-70	420	86
22	II-75	535	91
23	II-84	577	99

NDER 37 C.F.R. § 1.111 Attorney Docket No.: Q87920

AMENDMENT UNDER 37 C.F.R. § 1.111 U.S. Patent Application No.: 10/535,414

24	II-87	552	100
25	II-88	606	101
26	II-94	329	104
27	III-02	747	107
28	III-06	682	109
29	III-08	536	111
30	III-13	615	115
31	III-20	479	401
32	III-23	694	119
33	III-26	476	122
34	III-35	551	130
35	III-39	224	131
36	III-40	349	132
37	III-43	382	500
38	III-44	382	134
39	III-53	390	142
40	III-56	109	144
41	III-57	374	145
42	III-61	521	148
43	III-63	575	150
44	III-74	502	155
45	III-80	585	158
46	III-85	516	161
47	III-89	660	165
48	IV-14	545	275
49	IV-15	628	402
50	IV-26	494	403
51	IV-31	268	278
52	IV-32	569	279
53	IV-53	362	498

C.F.R. § 1.111 Attorney Docket No.: Q87920

AMENDMENT UNDER 37 C.F.R. § 1.111 U.S. Patent Application No.: 10/535,414

			<u> </u>
54	IV-69	286	4
55	IV-80	579	291
56	IX-10	641	314
57	IX-38	583	317
58	IX-39	424	318
59	IX-48	626	319
60	IX-77	556	325
61	V-03	496	296
62	V-04	397	297
63	V-07	293	298
64	V-11	599	404
65	V-12	498	301
66	V-55	421	499
67	V-80	260	311
68	VI-04	122	339
69	VI-07	405	1
70	VI-12	667	341
71	VI-14	642	343
72	VI-20	115	346
73	VI-23	634	347
74	VI-48	626	355
75	VI-50	585	356
76	VI-53	560	357
77	VI-55	509	359
78	VI-70	550	2
79	VI-74	655	365
80	VI-76	582	367
81	VI-87	595	370
82	VI-88	651	371
	VI-95	230	374
83	V 1-93	250	

	1		
85	VII-15	439	414
86	VII-19	580	171
87	VII-21	671	173
88	VII-32	457	179
89	VII-36	209	182
90	VII-39	541	183
91	VII-42	502	186
92	VII-43	316	187
93	VII-46	631	190
94	VII-47	526	415
95	VII-48	613	416
96	VII-59	565	199
97	VII-63	98	201
98	VII-66	362	204
99	VII-72	595	206
100	VII-73	522	207
101	VII-76	624	209
102	VII-77	692	418
103	VII-80	338	210
104	VII-81	556	211
105	VII-90	576	216
106	VII-91	341	
			217
107	VII-93	379	219
108	VIII-09	598	221
109	VIII-20	419	229
110	VIII-28	511	235
111	VIII-29	592	236
112	VIII-30	572	237
113	VIII-31	482	238
114	VIII-32	545	239
115	VIII-33	624	240
116	VIII-41	649	245

	1	T	
117	VIII-42	600	246
118	VIII-46	425	249
119	VIII-48	251	251
120	VIII-64	627	261
121	VIII-66	345	262
122	VIII-67	252	263
123	VIII-76	<del>691</del> <u>591</u>	270
124	X-07	641	328
125	X-15	132	329
126	X-29	370	331
127	X-54	603	334
128	X-56	71	335
129	X-68	642	421
130	X-72	622	336
131	X-94	<del>601</del> <u>501</u>	337
132	XI-13	620	423
133	XI-81	374	426
134	XII-07	567	427
135	XII-35	620	428
136	XII-59	484	430
137	XIII-19	559	433
138	XIII-52	513	378
139	XIII-92	741	435
140	XV-22	[[-]] <u>561</u>	388
141	XV-25	485	436
142	XVI-36	435	382
143	XVI-53	741	439
144	XVI-66	689	384
145	XVI-76	198	386
146	XVI-77	198	387
147	XVII-31	503	392

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q87920 U.S. Patent Application No.: 10/535,414

148	XVII-40	203	440
149	XVII-48	587	393
150	XVII-76	650	394
151	XVII-87	502	395
152	XVII-95	648	396

# Please replace Table 3 of the specification, previously amended July 6, 2009, with the following amended table:

Table 3

List of informative probes (Clone ID) selected for breast cancer diagnosis based on their occurrence criterion during variable selection

Occurrence*	Clone ID
100%	<u>XI-8,XVI-66,VIII-66,XVI-59,</u> VII-03,XIII-19,XII-35, <u>X-35,XI-50,XII-26,</u> IV-53, <u>XIII-29,XIII-62,</u> I-30,III-06,XV-22, <u>XV-94,</u> VII-15,VII-39,IX-39, <u>XVII-39,</u> III-40,VII-32
90%	<u>I-52,VI-65,VI-34,IV-62,XV-34,XVII-58,</u> V-11, <u>VI-78,XII-36,</u> XIII-92,VIII-29,XVI-53,XVI-77,XI-13, <u>XIII-84,</u> IV-14, <u>XII-31,</u> V-80,VII-48, <u>XVII-29,XVII-72</u>
80%	<u>III-60,VIII-74,IX-12,X-04,</u> XIII-52,VIII-30,IX-38
70%	<u>VI-49,</u> X-29,VIII-48
60%	<u>IV-82,</u> IX-10, <u>VI-52,</u> X-68,VII-77
50%	IV-15
40%	<u>XV-28,</u> II-70,V-55
30%	XVII-17,XVII-67
20%	<u>XI-58,</u> XVI-36, <u>VIII-39,VIII-44,</u> III-61,IV-69, <u>XV-68,</u> X-72
10%	<u>IX-42,</u> IX-77,X-94, <u>XV-96,XVII-55</u>
5%	XII-59,XVI-76,I-54, <u>XV-18,V-94,</u> X-54,VI-07,VII-47,XVII-31,XVII-87,XVII-48
In at least one model	II-41, <u>VI-41</u> ,III-57,III-89,VII-73,XV-25,IV-26, <u>X-34,IV-41</u> ,VII-90, <u>XV-42</u> ,XVII-82,XII-27,VIII-20,I-28, <u>VII-60</u> ,VIII-76,III-20, <u>VI-84,XI-07</u> ,XVII-28,XII-17,XVII-36,XII-52,XVII-76,VIII-46,VII-70, <u>XV-74,XV-93</u> ,VIII-31,II-87, <u>V-39</u> ,VI-55,X-07,X-15,XII-07, <u>XVII-07,XVII-08</u> ,XVII-95,I-24,IV-32, <u>V-32</u> ,VI-48, <u>VI-72</u> ,IV-80,IX-48,X-56, <u>XV-24,XII-32</u> ,XVII-40

<sup>\*100% =</sup> Genes appearing in all the 75 cross validated models; 90% = Additional genes appearing in at least 68 out of 75 cross validated models; 5% = Additional genes appearing in at least 4 out of 75 cross validated models and so on.

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q87920

U.S. Patent Application No.: 10/535,414

#### Please replace SEQ ID NO: 36 on page 128 of the Substitute Specification filed

#### October 3, 2008, with the following amended sequence:

Please replace SEQ ID NOs: 500, 501 and 499 on pages 277-278 of the Substitute Specification filed October 3, 2008, with the following amended sequences:

SEQ ID NO: <del>500</del>499 nt: 382

SEQ ID NO: 501500 nt:559

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q87920 U.S. Patent Application No.: 10/535,414

## AGGTGGAAGTCACCATTGCAGATGCTTAAGTCAACTATTTTAATAAATTGATGAC CAGTTGTTT

SEQ ID NO: 499501 nt: 464

CTATCATTGATCCAGGTGACTCTGACATCATTAGAAGCATGCCAGAACAGACTGG TGAAAAGTAQAACCTTTTCACCTACAAAATTTCACCTGCAAAACCTTAAAACCTGCAA AATTTTCCTTTAATAAAATTTGCTTG

GCGGCTGCTGTTGGTTGGGGGCCGTCCCGCTCCTAAGGCAGAAGATGGT
GGCCGCAAAGAAGACGAAAAAGTCGCTGGAGTCGATCAACTCTAGGCTCC
AACTCGTTATGAAAAGTGGGAAGTACGTCCTGGGGTACAAGCAGACTCTG
AAGATGATCAGACAAGGCAAAGCGAAATTGGTCATTCTCGCTAACAACTG
CCCAGCTTTGAGGAAATCTGAAATAGAGTACTATGCTATGTTGGCTAAAA
CTGGTGTCCATCACTACAGTGGCAATAATATTGAACTGGGCACAGCATGC
GGAAAATACTACAGAGTGTGCACACTGGCTATCATTGATCCAGGTGACTC
TGACATCATTAGAAGCATGCCAGAACAGACTGGTGAAAAGTAAACCTTTT
CACCTACAAAATTTCACCTGCAAACCTTAAACCTGCAAAATTTTCCTTTA
ATAAAATTTGCTTG